The normalization of disease-associated biomarkers, such as IL-10, a key molecular marker linked to ALS progression and reduced survival [62], provides biochemical evidence of genuine disease modification beyond patient perception or expectation. The gene discussed is IL10; the disease is amyotrophic lateral sclerosis.